RAI only useful to 40% of Thyroid Cancer patients

18 Posts | Page(s): Prev 1 2 

RE: RAI only useful to 40% of Thyroid Cancer patients

by nwerle on Fri May 24, 2019 09:37 AM

Quote | Reply

articel fails to detail if thyroidtectomy performed or not.

i could  see lower rate of 40% if leavign in cacnerous galnd

RE: RAI only useful to 40% of Thyroid Cancer patients

by ToddlerFather on Fri May 24, 2019 10:25 AM

Quote | Reply

On May 24, 2019 9:37 AM nwerle wrote:

articel fails to detail if thyroidtectomy performed or not.

i could  see lower rate of 40% if leavign in cacnerous galnd

Thyroidtectomy was a requirement to join the trial. 

RE: RAI only useful to 40% of Thyroid Cancer patients

by nwerle on Fri May 24, 2019 03:47 PM

Quote | Reply

so what are they doing FNA on?  a mass that returned?

RE: RAI only useful to 40% of Thyroid Cancer patients

by ToddlerFather on Fri May 24, 2019 04:36 PM

Quote | Reply

On May 24, 2019 3:47 PM nwerle wrote:

so what are they doing FNA on?  a mass that returned?

The options I saw were the patient to enroll before taking the thyroid out but after the decision of having TT, or to have previous tissue available for genetic testing. For instance, I would have been eligible, because the original thyroid tissue extracted from my surgery had gone thru genetic sequencing and the results are available. 

My understanding was that the requirements were about the primary tumor, not metastases or recurrence, although having such was required if the primary tumor wasn't large. 

On another topic, you previously mentioned 100 mCi as a small dose; it's not. The current guidelines is for using of up to 100 mCi. I had 200 mCi in my treatment, but that was years before the guidelines were updated. The current recommended maximum is 100 mCi, so the trial used the guideline reference, nothing less, nothing more. 

RE: RAI only useful to 40% of Thyroid Cancer patients

by butterfly501 on Sat May 25, 2019 01:28 AM

Quote | Reply

On May 24, 2019 3:47 PM nwerle wrote:

so what are they doing FNA on?  a mass that returned?

FNA? 

The clinical trial didn't have anything to do with FNAs. 

RE: RAI only useful to 40% of Thyroid Cancer patients

by butterfly501 on Sat May 25, 2019 01:31 AM

Quote | Reply

from the study details tab:

Official Title: A Randomised, Double Blind Study to Compare the Complete Remission Rate Following a 5-Week Course of Selumetinib or Placebo and Single Dose Adjuvant Radioactive Iodine Therapy in Patients With Differentiated Thyroid Cancer

Eligibility Criteria: 

Criteria

Inclusion Criteria:

Differentiated thyroid cancer Tumor >4 cm, or Gross extra-thyroid extension, or 1 lymph node >1 cm, or 5 or more lymph nodes of any size Previous thyroidectomy Must be able to receive radioactive iodine therapy Must be able to receive Thyroid Stimulating Hormone suppression

Exclusion criteria:

Metastaic disease Anaplastic thyroid cancer, medullary thyroid cancer or Hurthle cell carcinoma Presence of anti-Tg antibodies Previous treatment with any radiation Unresolved toxicity ≥ common terminology criteria for adverse event Grade 2

Ages Eligible for Study:   18 Years to 130 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

RE: RAI only useful to 40% of Thyroid Cancer patients

by ToddlerFather on Sat May 25, 2019 04:19 PM

Quote | Reply

One intriguing detail is that the only person I know that enrolled in this trial had Hurtle Cell. 

RE: RAI only useful to 40% of Thyroid Cancer patients

by butterfly501 on Sat Jun 01, 2019 09:28 PM

Quote | Reply

That must have been the person removed from the study for violating study protocol.

18 Posts | Page(s): Prev 1 2 
Subscribe to this message board discussion

Latest Messages

View More

We care about your feedback. Let us know how we can improve your CancerCompass experience.